Bioequivalence study of MTD201 (Q-Octreotide)
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Octreotide (Primary)
- Indications Acromegaly; Malignant carcinoid syndrome
- Focus First in man; Pharmacokinetics; Registrational
- Sponsors Midatech
- 14 Feb 2018 According to a Midatech media release, this trial is expected to complete in Q4 2018 / Q1 2019.
- 09 Jan 2018 According to a Midatech media release, initial exploratory phase is expected to complete by mid-2018, and the final confirmatory phase is expected to complete in H2 2018.
- 09 Jan 2018 According to a Midatech media release, this study has received oral confirmation from Polish regulators and Formal written confirmation of the approval is expected within the next two weeks.